Last Updated on March 2, 2026 by The Health Master
CDSCO
In a landmark move, the Central Drugs Standard Control Organisation (CDSCO) is preparing for a massive structural transformation aimed at closing manpower gaps and elevating Indian drug standards to match the likes of the USFDA.
Dr. Rajeev Singh Raghuvanshi, the Drugs Controller General of India (DCGI), recently shared a vision for a more transparent, efficient, and scientifically driven regulatory body.
This isn’t just a minor update; it’s a complete reimagining of how India monitors the medicines that reach billions of people globally.
Bridging the Audit Gap: The Rise of Notified Bodies
One of the most significant hurdles the CDSCO has faced is a simple numbers game.
here are thousands of manufacturing units across the country, but only a limited number of federal and state drug inspectors to visit them.
This has led to “blind spots” where certain drug categories haven’t seen a formal audit in years.
To solve this, the government has given an “in principle” nod to involve Quality Council of India (QCI) certified notified bodies.
-
What this means: Instead of relying solely on overworked government inspectors, the CDSCO will now leverage accredited third-party organizations to conduct rigorous audits.
-
The Global Blueprint: This shift mimics the European Union’s model, where Notified Bodies play a critical role under the European Medicines Agency (EMA) ecosystem to ensure products meet strict safety and quality standards before they hit the market.
Click for Guidance documents for industry
Currently, when a new drug protocol or a complex clinical trial comes across a desk at the CDSCO, the agency often has to call in outside experts.
While these experts are highly qualified, this “outsourcing” of knowledge prevents the CDSCO from building its own “institutional memory.”
Dr. Raghuvanshi highlighted the urgent need for an internal scientific cadre. By hiring specialized scientists to work directly within the agency, the CDSCO can:
-
Speed up the review of clinical and bioequivalence protocols.
-
Maintain a consistent database of past decisions and technical data.
-
Reduce the time it takes for life-saving drugs to get approved.
A Massive Recruitment Drive: 1,500 New Roles
To turn this vision into reality, the CDSCO is set to approach the government next month for a significant expansion.
The plan involves recruiting roughly 1,500 professionals focused on scientific review and clinical site evaluations.
This influx of talent is designed to make the Indian regulatory system not just “as good as” the USFDA, but potentially more streamlined and robust.
Comparison: Current vs. Proposed CDSCO Structure
| Feature | Current System | Proposed Reform |
| Audit Personnel | Only CDSCO & State Inspectors | Inspectors + QCI Notified Bodies |
| Scientific Review | Heavily dependent on external experts | Dedicated internal scientific cadre |
| Audit Coverage | Gaps in certain drug categories | 100% coverage across all segments |
| Global Alignment | Improving | Aligned with US FDA & EMA standards |
| Manpower | Understaffed for current volume | Addition of 1,500 specialized staff |
Why This Matters for the Global Market
When India strengthens its domestic oversight, it builds global confidence. In recent years, international regulators have scrutinized some Indian manufacturing sites.
By adopting a “self-correcting” mechanism through third-party audits and a stronger internal scientific team, India is sending a clear message: quality is non-negotiable.
This move will likely:
-
Boost Exports: Higher compliance levels make it easier for Indian pharma firms to enter regulated markets like the US and Japan.
-
Enhance Patient Safety: Rigorous audits mean fewer substandard medicines in circulation.
-
Accelerate Innovation: A faster, more scientific approval process encourages companies to invest in R&D within India.
FAQs
1. What is a “Notified Body” in the context of drug audits?
A notified body is an independent, third-party organization certified by the Quality Council of India (QCI). They are authorized to assess whether a manufacturer meets specific regulatory and quality standards.
2. Will third-party audits replace government inspections?
No. They are meant to complement and expand the current capacity. Government inspectors will still hold ultimate authority, but notified bodies will provide the “extra eyes” needed to cover the entire industry.
3. How will this affect the cost of medicines?
While better regulation involves some investment, it typically leads to fewer product recalls and smoother manufacturing processes, which can actually help stabilize long-term costs and improve market competitiveness.
4. When will the recruitment of the 1,500 personnel begin?
The CDSCO plans to seek formal government approval for this expansion next month. Once approved, the hiring process for the scientific cadre is expected to roll out in phases.
